Spleen tyrosine kinase (SYK) is indispensable in B-cell receptor signalling. SYK inhibitor entospletinib demonstrated clinical efficacy in patients with chronic lymphocytic leukaemia (CLL). However, pharmacodynamic effects of SYK inhibition in CLL cells and immunomodulatory effects of B-cell receptor-signalling inhibitors in patients with CLL are poorly understood. We conducted a phase 2 trial of entospletinib in combination with obinutuzumab, an anti-CD20 antibody, in 17 patients with relapsed/refractory CLL. Pharmacodynamic analysis demonstrated that treatment with entospletinib led to rapid downmodulation of pSTAT3 and the anti-apoptotic protein MCL1 in CLL cells. Meanwhile, 6 months of combination therapy was accompanied by a reduction in interferon-γ secretion in CD4 T-cells and a reversal of exhausted phenotype, as evidenced by downregulation of PD-1. Thus, SYK inhibition downmodulates MCL-1 and partially restores T-cell immunity in CLL. Trial registration number NCT03010358.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/bcp.14962 | DOI Listing |
Alzheimers Dement
December 2024
NYU Grossman School of Medicine, New York, NY, USA.
Background: Non-human primates (NHP) serve as an important bridge for testing therapeutic agents that have been previously shown to be effective in transgenic mouse models. Our earlier published data using an NHP model of sporadic AD-related pathology that develops abundant cerebral amyloid angiopathy (CAA), squirrel monkeys (SQMs), indicates that chronic treatment with TLR9 agonist, class B CpG ODN, safely ameliorates CAA while promoting cognitive benefits. In the present study, we intended to delineate alterations in brain metabolome induced by chronic CpG ODN administration in order to provide further insight into CpG ODN immunomodulatory capabilities.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Inserm, Sorbonne Université, Centre de Recherche Saint-Antoine, Immune System and Neuroinflammation Laboratory, Hôpital Saint-Antoine, Paris, France.
Background: Chronic innate neuroinflammation mediated by microglia and astrocytes in response to Aβ and pathological Tau species is a cardinal feature of AD that contributes to disease pathogenesis. Accumulating evidence now also highlight an instrumental role of T cells and peripheral-central immune crosstalk in the pathophysiology of AD. Both preclinical and clinical reports suggest the potential therapeutic interest of peripheral immunomodulatory approaches aimed at amplifying regulatory T cells (Tregs), e.
View Article and Find Full Text PDFDis Aquat Organ
January 2025
ICAR Research Complex for NEH Region, Umiam, Meghalaya PIN-793103, India.
The present study evaluated the immunomodulatory and disease resistance-enhancing effects of dietary supplementation of Withania somnifera root powder in Labeo rohita (22.10 ± 3.30 g, 12.
View Article and Find Full Text PDFCurr Mol Med
January 2025
Medical Laboratory Technology Department, Beirut Arab University, Beirut, Lebanon.
Cancer stem cells (CSCs) are the key drivers of tumorigenesis and relapse. A growing body of evidence reveals the tremendous power of CSCs to directly resist innate and adaptive anti-tumor immune responses. The immunomodulatory property gives CSCs the ability to control the tumor immune microenvironment (TIME).
View Article and Find Full Text PDFCurr Pharm Biotechnol
January 2025
Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.
Introduction: Iron oxide nanozyme was synthesized from the fruit peel extract of pomegranate, which served as a reducing agent during the green synthesis. The scavenging of reactive oxygen species is often accompanied by immunomodulation following antiproliferative effects due to the crosstalk between the proteins involved in the inter-related signaling pathways.
Method: In the current study, the green synthesized nanozyme was studied for its ability to induce apoptosis in breast cancer cell lines.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!